Lama Abdelnour, MD
Nephrology · Los Angeles, CANPI 1477817542
Payments from drug & device makers
Across 70 payments — averaging $3381.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$197K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
- Travere Therapeutics, Inc.$8K
- Vertex$6K
- Apellis Pharmaceuticals, Inc.$4K
- Calliditas Therapeutics US Inc.$3K
- plus $689 from 5 others
What the payments were for
- Consulting fees$30,73166%
- Speaking & faculty fees$8,50218%
- Travel & lodging$4,95811%
- Food & beverage$2,1785%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $196,984 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $17,509 |
| Travere Therapeutics, Inc. | 11 | $8,077 |
| Vertex | 11 | $6,475 |
| Apellis Pharmaceuticals, Inc. | 5 | $3,856 |
| Calliditas Therapeutics US Inc. | 4 | $3,104 |
| Vifor Pharma, Inc. | 1 | $200 |
| Baxter Healthcare | 3 | $179 |
| Aurinia Pharma U.S., Inc. | 2 | $146 |
| Otsuka America Pharmaceutical, Inc. | 1 | $145 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Empaveli$3,856
- Fabhalta$3,493
- TARPEYO$2,981
- Veltassa$200
- Renal - PD$109
How this compares
$236,695 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 25 | $139,092 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $57,801 |
| FarxigaDapagliflozin Propanediol | 56 | $56,832 |
| VelphoroSucroferric Oxyhydroxide | 21 | $23,917 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $15,585 |
| Sevelamer Carbonate | 46 | $15,476 |
| JardianceEmpagliflozin | 19 | $13,480 |
| DapagliflozinDapagliflozin Propanediol | 15 | $8,038 |
| Mycophenolate Mofetil | 19 | $7,930 |
| Nifedipine ErNifedipine | 175 | $5,741 |
| Potassium Citrate ErPotassium Citrate | 30 | $4,850 |
| ProsolParenteral Amino Acid 20% No.1 | 19 | $3,018 |
| Olmesartan Medoxomil | 59 | $2,422 |
| Labetalol Hcl | 52 | $2,090 |
| Calcitriol | 66 | $1,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $13,48019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.